Link as first comment.
#longevity #biotech #drugdevelopment #clinicaltrials #VAV1
Link as first comment.
#longevity #biotech #drugdevelopment #clinicaltrials #VAV1
https://inlightbio.com/news/?type=lic
https://inlightbio.com/news/?type=lic
https://openbionews.com/analysis/ai-in-bio-weekly-review-2026-11-06-to-12/
https://openbionews.com/analysis/ai-in-bio-weekly-review-2026-11-06-to-12/
Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones
#SEC #stocks #investing #EVMN #Mergers
🔗 secwatch.observer
Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones
#SEC #stocks #investing #EVMN #Mergers
🔗 secwatch.observer
https://www.stocktitan.net/news/EVMN/evommune-enters-into-agreement-to-in-license-evo570-a-potential-best-euu5np22wfuk.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EVMN/evommune-enters-into-agreement-to-in-license-evo570-a-potential-best-euu5np22wfuk.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/GLUE/monte-rosa-therapeutics-announces-milestone-achievement-associated-rfxvwevmxjkb.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/GLUE/monte-rosa-therapeutics-announces-milestone-achievement-associated-rfxvwevmxjkb.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CCCC/c4-therapeutics-unveils-expansion-of-discovery-platform-capabilities-s601qrnbwi5z.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CCCC/c4-therapeutics-unveils-expansion-of-discovery-platform-capabilities-s601qrnbwi5z.html?utm_source=stocktitan-bluesky&utm_medium=social
aurio9923.com/en/2026/10/2...
aurio9923.com/en/2026/10/2...
Link as first comment.
#longevity #geroscience #InsilicoMedicine #ISM9546 #autoimmunedisease
Link as first comment.
#longevity #geroscience #InsilicoMedicine #ISM9546 #autoimmunedisease
->Nature | More on "Cancer immunotherapy and immune cells" at BigEarthData.ai
www.youtube.com/watch?v=VAv1...
www.youtube.com/watch?v=VAv1...
改正個人情報保護法はEUの保護水準を満たしているのか? 弁護士らがEUに意見書提出し十分性認定の是非を問います。 10月6日記者会見
#保団連
全国保険医団体連合会公式チャンネル
www.youtube.com/watch?v=VAv1...
改正個人情報保護法はEUの保護水準を満たしているのか? 弁護士らがEUに意見書提出し十分性認定の是非を問います。 10月6日記者会見
#保団連
全国保険医団体連合会公式チャンネル
www.youtube.com/watch?v=VAv1...
Medicine · Phys.org
#Medicine #MedSky
On September 8, 2026, Monte Rosa Therapeutics, Inc. issued a press release announcing the achievement of a milestone associated with the initiation of a Phase 2 clinical study for the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in participants with Sjögren’s disease.
On September 8, 2026, Monte Rosa Therapeutics, Inc. issued a press release announcing the achievement of a milestone associated with the initiation of a Phase 2 clinical study for the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in participants with Sjögren’s disease.
Beyond the G-Loop: CRBN Molecular Glues Potently Target VAV1 via a Novel SH3 RT-Loop Degron
www.biorxiv.org/content/10.1...
#TPD #Targeted_Protein_Degradation #CRBN
Beyond the G-Loop: CRBN Molecular Glues Potently Target VAV1 via a Novel SH3 RT-Loop Degron
www.biorxiv.org/content/10.1...
#TPD #Targeted_Protein_Degradation #CRBN